Aikaterini Gkouvi1,2,3,4, Electra Nicolaidou1,2,3,4, Andreas Corbo1,2,3,4, Gennaro Selvaggi1,2,3,4, Antonis Tsimpidakis1,2,3,4, Styliani Mastraftsi1,2,3,4, Stamatios Gregoriou1,2,3,4. 1. Dr. Gkouvi is in private practice in Thessaloniki, Greece. 2. Drs. Nicolaidou, Tsimpidakis, Mastraftsi, and Gregoriou are with the First Department of Dermatology-Venereology, Faculty of Medicine at the National and Kapodistrian University of Athens in Athens, Greece. 3. Dr. Corbo is in private practice in Rome, Italy and with the University of Tor Vergata in Rome, Italy. 4. Dr. Selvaggi is with the Department of Plastic Surgery at the Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg and Sahlgrenska University Hospital in Gothenburg, Sweden.
Abstract
BACKGROUND: There is still an unsatisfied need for new treatments for vitiligo with more rapid onset and long-term sustainability of repigmentation. OBJECTIVE: We sought to evaluate the possible efficacy of heterologous type I collagen as an add-on therapy to narrowband ultraviolet B (NB-UVB) for the treatment of vitiligo. METHODS: Five patients with non-segmental vitiligo older than 18 years with bilateral and approximately symmetrical vitiligo lesions that did not evolve in size for at least six months were included. All vitiligo lesions were treated with NB-UVB therapy according to the Vitiligo Working Group recommendations. Two selected nonfacial lesions of each patient were also treated with intradermal injections of heterologous type I collagen (HTIC) every two weeks. Repigmentation of HTIC plus NB-UVB-treated lesions and their symmetrical counterparts treated just with NB-UVB was evaluated at baseline and Week 12. RESULTS: Repigmentation of the HTIC-injected lesions started after the first treatment session in three cases and after the second session in two cases. After six sessions (Week 12), the mean repigmentation rate was 70.5 percent (95% confidence interval:0.569-0.841) in the NB-UVB plus HTIC treatment group versus 16.5 percent (95% confidence interval: 0.137-0.192) in NB-UVB treatment group (p=0.0006, paired t-test). CONCLUSION: Although the number of patients treated with the combination treatment was limited in our study, our results suggest that the addition of HTIC to NB-UVB therapy might offer a more rapid onset of repigmentation in patients with vitiligo.
BACKGROUND: There is still an unsatisfied need for new treatments for vitiligo with more rapid onset and long-term sustainability of repigmentation. OBJECTIVE: We sought to evaluate the possible efficacy of heterologous type I collagen as an add-on therapy to narrowband ultraviolet B (NB-UVB) for the treatment of vitiligo. METHODS: Five patients with non-segmental vitiligo older than 18 years with bilateral and approximately symmetrical vitiligo lesions that did not evolve in size for at least six months were included. All vitiligo lesions were treated with NB-UVB therapy according to the Vitiligo Working Group recommendations. Two selected nonfacial lesions of each patient were also treated with intradermal injections of heterologous type I collagen (HTIC) every two weeks. Repigmentation of HTIC plus NB-UVB-treated lesions and their symmetrical counterparts treated just with NB-UVB was evaluated at baseline and Week 12. RESULTS: Repigmentation of the HTIC-injected lesions started after the first treatment session in three cases and after the second session in two cases. After six sessions (Week 12), the mean repigmentation rate was 70.5 percent (95% confidence interval:0.569-0.841) in the NB-UVB plus HTIC treatment group versus 16.5 percent (95% confidence interval: 0.137-0.192) in NB-UVB treatment group (p=0.0006, paired t-test). CONCLUSION: Although the number of patients treated with the combination treatment was limited in our study, our results suggest that the addition of HTIC to NB-UVB therapy might offer a more rapid onset of repigmentation in patients with vitiligo.
Authors: Tasneem F Mohammad; Mohammed Al-Jamal; Iltefat H Hamzavi; John E Harris; Giovanni Leone; Raúl Cabrera; Henry W Lim; Amit G Pandya; Samia M Esmat Journal: J Am Acad Dermatol Date: 2017-02-16 Impact factor: 11.527
Authors: Zalfa A Abdel-Malek; Christian Jordan; Tina Ho; Parth Rajendrakumar Upadhyay; Alan Fleischer; Iltefat Hamzavi Journal: Pigment Cell Melanoma Res Date: 2020-04-12 Impact factor: 4.693